Inhibrx Biosciences (INBX) Common Equity (2023 - 2025)

Inhibrx Biosciences (INBX) has 3 years of Common Equity data on file, last reported at $8.0 million in Q4 2025.

• On a quarterly basis, Common Equity fell 94.02% year-over-year to $8.0 million in Q4 2025; TTM through Dec 2025 was $8.0 million, a 94.02% decrease from a year earlier, with the FY2025 full-year figure at $8.0 million, down 94.02% from the prior year.
• Common Equity for Q4 2025 stood at $8.0 million, down from $36.8 million in the prior quarter.
• Over the last five years, Common Equity for INBX reached as high as $219.4 million in Q2 2024 and fell as low as -$24.8 million in Q2 2023.
• Historically, Common Equity has averaged $81.7 million across 3 years, with a median of $68.6 million in 2025.
• Across the five-year window, Common Equity surged 984.11% in 2024 and slumped 94.02% in 2025, its largest moves.
• Year by year, Common Equity stood at $43.5 million in 2023, then jumped by 207.07% to $133.6 million in 2024, then slumped by 94.02% to $8.0 million in 2025.
• Per Business Quant data, the three most recent Common Equity figures were $8.0 million in Q4 2025, $36.8 million in Q3 2025, and $68.6 million in Q2 2025.